Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sino Biopharma Invests in Karolinska; Deals Ahead?

publication date: Nov 17, 2014
Sino Biopharmaceutical will make an investment of up to $128.5 million in Karolinska Development AB, a Stockholm firm that supports translational drug development in Scandinavia. Typically, Karolinska invests in innovative academic-based concepts, bringing them to a point where they can be partnered. It currently has at least a dozen companies in its portfolio. According to Karolinska, it wanted to have a "strong Asian specialist investor" in life science, with the clear implication that future deals would be made between the two companies. More details....

Stock Symbols: (HK: 1177) (SS: KDEV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital